Centocor Remicade
Executive Summary
Placebo arm of Phase III rheumatoid arthritis trial (ATTRACT) has been unblinded after investigators discovered greater efficacy for infliximab in one-year x-ray data. The two-year 428-patient trial will keep the four methotrexate/Remicade treatment arms blinded but methotrexate/placebo patients will be given the option to roll into an open-label trial (PROMPT) and use low-dose Remicade (3 mg/kg every eight weeks) in combination with methotrexate. The x-ray data will be presented at the American College of Rheumatology annual meeting in Boston on Nov. 15. Centocor also denied rumors that Lilly has made an offer to purchase the company (1"The Pink Sheet" Sept. 13, p. 5)
You may also be interested in...
Remicade Rheumatoid Arthritis X-Ray Data Sealed J&J Purchase Of Centocor
Interim data from Centocor's Remicade in rheumatoid arthritis, initially available to the company in mid-June, convinced Johnson & Johnson to purchase the biotechnology company.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials